Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis

Zhang, Xu; Sun, Lingzhi

doi:10.3892/mco.2017.1524

Cited by 4 publications

(2 citation statements)

References 31 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor: Higher levels of C3 protein in cancerous tissues than in adjacent normal pancreatic tissues [79] Pancreatic cancer Tumor: Higher levels of C3 protein in cancerous tissues than in normal pancreatic tissues [80] C3a Esophageal cancer Plasma: Higher C3a levels in patients than healthy donors [81] C3a desArg Breast cancer Plasma: Higher C3a desArg level in patients than healthy donors [82] C5a…”

Section: C3mentioning

confidence: 99%

Complement System: Promoter or Suppressor of Cancer Progression?

et al. 2020

View full text Add to dashboard Cite

Constituent of innate immunity, complement is present in the tumor microenvironment. The functions of complement include clearance of pathogens and maintenance of homeostasis, and as such could contribute to an anti-tumoral role in the context of certain cancers. However, multiple lines of evidence show that in many cancers, complement has pro-tumoral actions. The large number of complement molecules (over 30), the diversity of their functions (related or not to the complement cascade), and the variety of cancer types make the complement-cancer topic a very complex matter that has just started to be unraveled. With this review we highlight the context-dependent role of complement in cancer. Recent studies revealed that depending of the cancer type, complement can be pro or anti-tumoral and, even for the same type of cancer, different models presented opposite effects. We aim to clarify the current knowledge of the role of complement in human cancers and the insights from mouse models. Using our classification of human cancers based on the prognostic impact of the overexpression of complement genes, we emphasize the strong potential for therapeutic targeting the complement system in selected subgroups of cancer patients.

show abstract

Section: C3mentioning

confidence: 99%

Complement System: Promoter or Suppressor of Cancer Progression?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The advantage of this technology is the integration of on-chip selective and sensitive capture, partial characterization of the analyte, and relative quantitation. SELDI-TOF MS has been employed for the diagnosis, detection, and identification of biomarker candidates for various cancer types, such as prostate [ 101 ], pancreatic [ 102 ], lung [ 103 ], breast [ 104 ], melanoma [ 105 ], colon [ 106 ], oral squamous cell carcinoma [ 107 ], gastric [ 108 , 109 ], ovarian [ 110 , 111 ], liver [ 112 ], renal [ 113 ], and esophageal [ 114 , 115 ].…”

Section: Advances In Proteomic Technologies Used In the Study Of Cancermentioning

confidence: 99%

Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice

Punetha

Kotiya

2023

Proteomes

View full text Add to dashboard Cite

Proteomics continues to forge significant strides in the discovery of essential biological processes, uncovering valuable information on the identity, global protein abundance, protein modifications, proteoform levels, and signal transduction pathways. Cancer is a complicated and heterogeneous disease, and the onset and progression involve multiple dysregulated proteoforms and their downstream signaling pathways. These are modulated by various factors such as molecular, genetic, tissue, cellular, ethnic/racial, socioeconomic status, environmental, and demographic differences that vary with time. The knowledge of cancer has improved the treatment and clinical management; however, the survival rates have not increased significantly, and cancer remains a major cause of mortality. Oncoproteomics studies help to develop and validate proteomics technologies for routine application in clinical laboratories for (1) diagnostic and prognostic categorization of cancer, (2) real-time monitoring of treatment, (3) assessing drug efficacy and toxicity, (4) therapeutic modulations based on the changes with prognosis and drug resistance, and (5) personalized medication. Investigation of tumor-specific proteomic profiles in conjunction with healthy controls provides crucial information in mechanistic studies on tumorigenesis, metastasis, and drug resistance. This review provides an overview of proteomics technologies that assist the discovery of novel drug targets, biomarkers for early detection, surveillance, prognosis, drug monitoring, and tailoring therapy to the cancer patient. The information gained from such technologies has drastically improved cancer research. We further provide exemplars from recent oncoproteomics applications in the discovery of biomarkers in various cancers, drug discovery, and clinical treatment. Overall, the future of oncoproteomics holds enormous potential for translating technologies from the bench to the bedside.

show abstract

Inside-Out of Complement in Cancer

et al. 2022

View full text Add to dashboard Cite

The role of complement in cancer has received increasing attention over the last decade. Recent studies provide compelling evidence that complement accelerates cancer progression. Despite the pivotal role of complement in fighting microbes, complement seems to suppress antitumor immunity via regulation of host cell in the tumor microenvironment. Although most studies link complement in cancer to complement activation in the extracellular space, the discovery of intracellular activation of complement, raises the question: what is the relevance of this process for malignancy? Intracellular activation is pivotal for the survival of immune cells. Therefore, complement can be important for tumor cell survival and growth regardless of the role in immunosuppression. On the other hand, because intracellular complement (the complosome) is indispensable for activation of T cells, these functions will be essential for priming antitumor T cell responses. Here, we review functions of complement in cancer with the consideration of extra and intracellular pathways of complement activation and spatial distribution of complement proteins in tumors and periphery and provide our take on potential significance of complement as biomarker and target for cancer therapy.

show abstract

Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis

Cited by 4 publications

References 31 publications

Complement System: Promoter or Suppressor of Cancer Progression?

Complement System: Promoter or Suppressor of Cancer Progression?

Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice

Inside-Out of Complement in Cancer

Contact Info

Product

Resources

About